Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Genmu, Kadokura"'
Autor:
Genmu Kadokura, Shogen Boku, Takaaki Yokoyama, Takuma Onoe, Hideki Sakai, Koji Matsumoto, Satoshi Morita, Noriyuki Katsumata, Meiko Nishimura
Publikováno v:
International Journal of Clinical Oncology
Background Carboplatin is a key drug for ovarian cancer. However, it sometimes induces hypersensitivity reactions (HSRs) that result in the discontinuation of the treatment. Although various desensitization protocols have been reported in previous re
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 43(2)
A 32 year-old man was diagnosed with retroperitoneal choriocarcinoma with metastasis to the lungs and liver. One cycle of modified BEP regimen did not sufficiently decrease the hCG. Therefore, we chose the GETUG 13 protocol of dose dense chemotherapy
Autor:
Genmu, Kadokura, Noriyuki, Katsumata
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 41(4)
The prognosis of cancer patients with anemia is poor. In Japan, these patients are treated only with red blood cell transfusions, and doctors cannot use erythropoiesis stimulating agents(ESAs)such as epoetin and darbepoetin. On the other hand, ESAs a
Publikováno v:
Journal of Clinical Oncology. 33:e20601-e20601
e20601 Background: Many people seek a second opinion to hear different opinions on the best treatment options and to learn more about the cancer. There are few reports on second-opinion seeking in ...
Publikováno v:
Annals of Oncology. 25:v102
Background: The combination of carboplatin and other cytotoxic drug is the current standard chemotherapy regimen for platinum sensitive recurrent epithelial ovarian, and peritoneal cancer. Hypersensitivity reaction (HSR) is one of adverse events of p
Autor:
Hitomi Sakai, Noriyuki Katsumata, Genmu Kadokura, Sakai, Hitomi, Katsumata, Noriyuki, Kadokura, Genmu
Publikováno v:
BMC Cancer; 10/6/2015, Vol. 15 Issue 1, p1-8, 8p, 5 Charts
Publikováno v:
BMC Cancer
Background This analysis was undertaken to evaluate the practice patterns of Japanese physicians regarding curative-intent chemotherapy, especially in outpatient settings, and to define factors negatively affecting the maintenance of relative dose in